Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response (Cancer Drug Discovery and Development) (Hardcover)

About this book
The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional
approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most
cases the majority of treated patients do not have significant benefits from the treatment while they often experience
moderate to severe toxicities. In "Pharmacogenomics, Anticancer Drug Discovery, and Response," edited by Federico
Innocenti, readers will find a series of chapters addressing the role of genomic information in cancer therapy and in
drug development representing a unique source, as it describes experimental approaches, statistical strategies, and
clinical examples of the application of genomic medicine in oncology. This book provides the most comprehensive body of
knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.

Written for:
Cancer pharmacogenomics and clinicians, students

Keywords:
MicroRNAs
Microarrays
Oncology drug development
Pharmacogenomics
Toxicogenomics
anticancer drug response
oncology
proteomic analysis
tumor DNA

Table of contents
pharmacoGENOMICS, ANTICANCER DRUG DISCOVERY, AND RESPONSE


Book editor: Federico Innocenti, M.D., Ph.D.


Genomic experimental approaches in oncology


Toward the realisation of the promise of microarrays in oncology

Neil Winegarden


Cell based models to identify genetic variants contributing to anticancer drug response

M. Eileen Dolan


Proteomic analysis in cancer patients

Kazuyuki Nakamura


MicroRNAs and discovery of new targets

Gozoh Tsujimoto


Pharmacogenomics of the National Cancer Institute’s 60 tumor cell panel

David G. Covell


Use of single nucleotide polymorphism array for tumor aberrations in gene copy numbers

Kwong-Kwok Wong


Pharmacogenomics of toxicity and response of chemotherapy


Concordance between tumor and germline DNA

Sharon Marsh


Epidermal growth factor receptor mutations and sensitivity to selective kinase inhibitors in human lung cancer

Jeffrey Settleman

3. BCR-ABL mutations and imatinib resistance in chronic myeloid leukemia patients

Mark Litzow


Role of thymidylate synthase gene variations in colorectal cancer patients

Heinz-Josef Lenz


Thiopurines in the treatment of childhood acute lymphoblastic leukemia and genetic variants in the thiopurine S-
methyltransferase gene

Martin Stanulla


The impact of polymorphisms on the clinical outcomes of monoclonal antibody therapy against hematologic malignancies

Dong Hwan Kim


DNA repair and mitotic check point genes as potential predictors of chemotherapy response in non-small-cell lung cancer

Rafael Rosell


Dihydropyrimidine dehydrogenase (DPYD) gene polymorphism: portrait of a serial killer.

Gerard Milano


Impact of UDP-glucuronosyltransferase 1A haplotypes on irinotecan treatment

Kimie Sai


Microarray profiling in breast cancer patients

Lan Guo

11. Role of the folate pathway and the thymidylate synthase genes in pediatric acute lymphoblastic leukemia treatment
response

Richard Aplenc


Pharmacogenomics in clinical drug development in oncology


Pharmacogenomics in drug development: an pharmaceutical industry perspective

Tal Zaks


Identification of a pharmacogenomic biomarker classifiers in cancer drug development

Richard Simon


Toxicogenomics application to oncology drug development

Teresa Lettieri


Strategies to identify pharmacogenomic biomarkers: candidate gene, pathway-based, and genome-wide approaches

Xifeng Wu